Fidelity International
BIO icon

Fidelity International’s Bio-Rad Laboratories Class A BIO Stock Holding History

Fidelity International’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-539
Closed -$180K – 920
2024
Q3 		$180K Buy
+539
New +$171K ﹤0.01% 830
2021
Q2 		– Sell
-2
Closed -$1K – 880
2021
Q1 		$1K Hold
2
– – ﹤0.01% 888
2020
Q4 		$1K Hold
2
– – ﹤0.01% 856
2020
Q3 		$1K Hold
2
– – ﹤0.01% 856
2020
Q2 		$1K Sell
2
-33,205
-100% -$14.7M ﹤0.01% 831
2020
Q1 		$11.6M Buy
+33,207
New +$12.2M 0.02% 429
2018
Q4 		– Sell
-27,188
Closed -$8.51M – 854
2018
Q3 		$8.51M Sell
27,188
-27,162
-50% -$8.43M 0.01% 500
2018
Q2 		$15.7M Sell
54,350
-14,600
-21% -$4.03M 0.02% 431
2018
Q1 		$17.2M Buy
68,950
+26,469
+62% +$6.74M 0.05% 286
2017
Q4 		$10.1M Hold
42,481
– – 0.03% 350
2017
Q3 		$9.44M Buy
42,481
+30,559
+256% +$6.88M 0.03% 346
2017
Q2 		$2.7M Buy
+11,922
New +$2.6M 0.01% 436

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Fidelity International's BIO Position: Q4 2024 in Review

Fidelity International sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 539 shares — an estimated $180K sold.

Fidelity International first reported a position in BIO in Q2 2017 and held it in 12 quarters. The position peaked at $17.2M in Q1 2018. 457 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

  • Fidelity International reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
  • Fidelity International sold 539 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $180K.
  • Fidelity International first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and held it in 12 quarters.
  • Fidelity International's Bio-Rad Laboratories Class A position peaked at $17.2M in Q1 2018.
  • 457 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Fidelity International's 13F filing for Q4 2024, filed 13 Feb 2025.